Xian Shen, PhD
Articles
Sacubitril/Valsartan in Medicare Alternative Payment Models
Optimizing utilization of sacubitril/valsartan for treatment of heart failure could improve provider performance in the Bundled Payments for Care Improvement initiative and the Medicare Shared Savings Program.
Impact of Formulary Restrictions on Medication Intensification in Diabetes Treatment
Formulary restrictions on brand name noninsulin antihyperglycemic drugs have little impact on treatment intensification patterns among low-income patients with diabetes in Medicare Part D.
Impact of Formulary Restrictions on Medication Use and Costs
Placing formulary restrictions on brand name drugs shifts use toward generics, lowers the cost per prescription fill, and has minimal impact on overall adherence for antidiabetes, antihyperlipidemia, and antihypertension medications among low-income subsidy recipients in Medicare Part D plans.
